糖尿病视网膜病变治疗药物的开发进展  

Internal medicine treatment of diabetic retinopathy

作　　者：谢瑞满[1,2] 

机构地区：[1]复旦大学附属中山医院老年科 [2]复旦大学附属中山医院神经科

出　　处：《世界临床药物》2008年第11期661-665,共5页World Clinical Drug

摘　　要：糖尿病视网膜病变(DR)是糖尿病最常见和最严重的微血管并发症之一,其基本病理改变是血-视网膜屏障破坏及新生血管形成。目前DR的防治由以往的控制危险因素、单一提高胰岛素的降糖作用等简单原则,发展到调节葡萄糖代谢、增加胰岛素受体敏感性、抑制胰岛素抵抗及糖基化终末产物的形成、减少氧化应激等多方面。本文综述血糖控制、特殊治疗药物和中医药早期防治等用于DR内科治疗的药物的开发进展。Diabetic retinopathy （DR） is one of the most common and severe microangium complications of diabetes mellitus, the fundamental pathological characteristic of which is breakdown of the blood-retinal barrier and neovascularization. In the later stage of DR, the shrinkage of the neovascular membrane, which may tractates the retina and produce detachment of the retina, results in progressive deterioration of vision. Retinal neovascularization results from both increasing of vascular stimulating factor such as vascular endothelial growth factor （VEGF） and reducing of vascular inhibiting factor such as pigment epithelium-derived factor （PEDF）. This article summarized the advancement in prevention and treatment of DR and provided ideas for medicine therapeutic to DR.

关 键 词：糖尿病视网膜病变 血管内皮生长因子 色素上皮衍生因子 临床治疗 

分 类 号：R587.2[医药卫生—内分泌]